Ashley Winslow joins Odylia Therapeutics as Chief Scientific Officer

Dr. Winslow will oversee scientific operations and strategy development with a focus on expanding partnerships to enable Odylia to change the way gene therapies are brought to clinic.  Dr. Winslow states, “Odylia presents an amazing opportunity to shift the paradigm for ultra-rare disease drug development and bring life-changing treatments to people living with rare disease, regardless of prevalence or commercial interest. I’m excited to be part of the organization especially as we embark on our lead program, RPGRIP1.”

Dr. Winslow comes to Odylia most recently from the Orphan Disease Center at the University of Pennsylvania where she was the Senior Director of Portfolio Development and Translational Research.  Prior to the Orphan Disease Center, she worked at Pfizer as an Associate Director of Neuroscience Genetics.  Dr. Winslow received her Ph.D. from the University of Cambridge in Medical Genetics and Molecular Cell Biology and completed her Bachelors degrees in Chemistry and Anthropology from the University of Florida.

“We are thrilled to have Ashley join Odylia,” said Scott Dorfman, Odylia’s Chief Executive Officer. “Her expertise in gene therapy and clinical development as well as her strength in partnership building positions us for our next phase of growth as an organization.  I believe Odylia can truly achieve our goal of bringing rare targets to the clinic with Dr. Winslow at the helm.”